A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients

BACKGROUND: Lumiracoxib is a selective cyclooxygenase-2 inhibitor effective in the treatment of osteoarthritis (OA) with a superior gastrointestinal (GI) safety profile as compared to traditional non-steroidal anti-inflammatory drugs (NSAIDs, ibuprofen and naproxen). This safety study compared the G...

Descripción completa

Detalles Bibliográficos
Autores principales: Stricker, Kirstin, Yu, Sue, Krammer, Gerhard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542997/
https://www.ncbi.nlm.nih.gov/pubmed/18778469
http://dx.doi.org/10.1186/1471-2474-9-118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2542997/
https://www.ncbi.nlm.nih.gov/pubmed/18778469
http://dx.doi.org/10.1186/1471-2474-9-118

Ejemplares similares